This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 1999;117:518-519.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ALTHOUGH THE new and popular impotence drug sildenafil (Viagra; Pfizer Pharmaceuticals, New York, NY) is prescribed for indications outside the field of ophthalmology, there are several reasons why ophthalmologists need to be informed about the pharmacologic characteristics of this agent and its potential side effects. The drug is intended primarily for older men with vascular disease that impairs their ability to have an erection, and many of these individuals see ophthalmologists for ocular disorders of aging, such as macular degeneration, or ocular vascular disease, such as diabetic retinopathy. A second point of relevance is that the drug has a direct effect on the retina,¹ which probably accounts for many of the visual side effects that have been reported. We must be able to reassure patients (and our medical colleagues) about acceptable side effects while warning them of potential toxic effects. A third concern is that because of the great demand . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sildenafil-Mediated Reduction in Retinal Function in Heterozygous Mice Lacking the {{gamma}}-Subunit of Phosphodiesterase
Behn and Potter
IOVS 2001;42:523-527.
ABSTRACT | FULL TEXT